FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

Dec 8, 2024 0 1.8k
Jan 28, 2025 0 391
Sep 21, 2024 0 361
Nov 21, 2024 0 300
May 7, 2024 0 246
News headlines uses cookies. By continuing to browse the site you are agreeing to our TERMS and to use of cookies.